Microbot Medical (MBOT) Liabilities and Shareholders Equity (2010 - 2026)

Microbot Medical (MBOT) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $78.1 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 152.71% year-over-year to $78.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $274.5 million (up 453.82% YoY) and the FY2025 annual result came in at $81.5 million, up 1252.08% from the prior year.
• Liabilities and Shareholders Equity eased to $78.1 million in Q1 2026, from $81.5 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $81.8 million in Q3 2025 to a low of $5.2 million in Q3 2024.
• A 5-year average of $23.9 million and a median of $9.5 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity slumped 62.39% — and 2025, when it soared 1469.89%.
• Tracing MBOT's Liabilities and Shareholders Equity over 5 years: stood at $9.5 million in 2022, then decreased by 12.69% to $8.3 million in 2023, then fell by 27.57% to $6.0 million in 2024, then surged by 1252.08% to $81.5 million in 2025, then fell by 4.27% to $78.1 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $78.1 million (Q1 2026), $81.5 million (Q4 2025), and $81.8 million (Q3 2025), per Business Quant data.